In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Ligand, TAP develop androgen receptor modulators; concluded

Executive Summary

Ligand Pharmaceuticals (gene transcription technology) and TAP Pharmaceutical Products (the US joint venture of Takeda Chemical and Abbott Laboratories) will jointly discover and develop selective androgen receptor modulators (SARMs) for treating diseases in the areas of urology, gynecology, and endocrinology.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract

Related Companies

UsernamePublicRestriction

Register